Evidence map›Paper›PMID 32966316›Full record

ArticlePloS one2020

Detection of acute toxicity of aflatoxin B1 to human hepatocytes in vitro and in vivo using chimeric mice with humanized livers.

Yuji Ishida, Chihiro Yamasaki, Hiroko Iwanari, Hisahiko Yamashita, Yuko Ogawa, Ami Yanagi, Suzue Furukawa, Yuha Kojima, Kazuaki Chayama, Junichi Kamiie and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Vitamin U Attenuates Acute Aflatoxin BVeterinary sciences · 2026
    Article
  2. Research status of several programmed cell death in the toxic effect of AFBApoptosis : an international journal on programmed cell death · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Yuji IshidaDepartment of Research and Development, PhoenixBio Co., Ltd., Higashi-Hiroshima, Hiroshima, Japan.ORCID 0000-0003-1855-6325
Chihiro YamasakiDepartment of Research and Development, PhoenixBio Co., Ltd., Higashi-Hiroshima, Hiroshima, Japan.
Hiroko IwanariQuantitative Biology and Medicine, Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Meguro, Tokyo, Japan.
Hisahiko YamashitaInstitute of Immunology Co., Ltd., Bunkyo, Tokyo, Japan.
Yuko OgawaDepartment of Research and Development, PhoenixBio Co., Ltd., Higashi-Hiroshima, Hiroshima, Japan.
Ami YanagiDepartment of Research and Development, PhoenixBio Co., Ltd., Higashi-Hiroshima, Hiroshima, Japan.
Suzue FurukawaDepartment of Research and Development, PhoenixBio Co., Ltd., Higashi-Hiroshima, Hiroshima, Japan.
Yuha KojimaDepartment of Research and Development, PhoenixBio Co., Ltd., Higashi-Hiroshima, Hiroshima, Japan.
Kazuaki ChayamaResearch Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Hiroshima, Japan.
Junichi KamiieLaboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, Sagamihara, Kanagawa, Japan.
Chise TatenoDepartment of Research and Development, PhoenixBio Co., Ltd., Higashi-Hiroshima, Hiroshima, Japan.ORCID 0000-0002-2640-3268
PhoenixBio (Japan) · JPHiroshima University · JPAzabu University · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aflatoxin B1 (AFB1), a mycotoxin, is acutely hepatotoxic to many animals including humans. However, there are marked interspecies differences in sensitivity to AFB1-induced toxicity depending on bioactivation by cytochrome P450s (CYPs). In the present study, we examined the applicability of chimeric mice with humanized livers and derived fresh human hepatocytes for in vivo and vitro studies on AFB1 cytotoxicity to human hepatocytes. Chimeric mice with highly humanized livers and SCID mice received daily injections of vehicle (corn oil), AFB1 (3 mg/kg), and carbon tetrachloride (50 mg/kg) for 2 days. Histological analysis revealed that AFB1 promoted hepatocyte vacuolation and inflammatory cell infiltration in the area containing human hepatocytes. A novel human alanine aminotransferase 1 specific enzyme-linked immunosorbent assay demonstrated the acute toxicity of AFB1 to human hepatocytes in the chimeric mouse livers. The sensitivity of cultured fresh human hepatocytes isolated from the humanized liver mice for AFB1 cytotoxicity was comparable to that of primary human hepatocytes. Long-term exposure to AFB1 (6 or 14 days) produced a more severe cytotoxicity. The half-maximal lethal concentration was 10 times lower in the 2-week treatment than after 2 days of exposure. Lastly, the significant reduction of AFB1 cytotoxicity by a pan-CYP inhibitor or transfection with CYP3A4 specific siRNA clearly suggested that bioactivation of AFB1 catalyzed by CYPs was essential for AFB1 cytotoxicity to the human hepatocytes in our mouse model. Collectively, our results implicate the humanized liver mice and derived fresh human hepatocytes are useful models for studies of AFB1 cytotoxicity to human hepatocytes.

Indexed as

Activation, MetabolicAflatoxin B1AnimalsCytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemHepatocytesHumansIn Vitro TechniquesLethal Dose 50Liver TransplantationMaleMiceMice, SCIDRNA, Small InterferingTransplantation ChimeraAflatoxin B1CYP3A4 protein, humanCytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemRNA, Small Interfering

Identifiers

PMID32966316
PMCPMC7510964
OpenAlexW3088912891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.